2023 Form 5500 filing — Karyopharm Therapeutics Inc. 401(K) Plan

Plain-English filing summary

According to public Form 5500 filings published through the U.S. Department of Labor (DOL) Employee Benefits Security Administration (EBSA) via the EFAST2 system, this is the 2023 Form 5500 filing (EFAST2 acknowledgement 20240910114713NAL0009880848001) for Karyopharm Therapeutics Inc. 401(K) Plan, reported by Karyopharm Therapeutics Inc. under EIN 26-3931704 and plan number 001. It reports 597 participants. Attached schedules in the loaded dataset include Schedule H (large plan financials), Schedule C (service provider compensation).

EFAST2 acknowledgement
20240910114713NAL0009880848001
Filing year
2023
Form type
2
Plan sponsor
Karyopharm Therapeutics Inc.
EIN
26-3931704
Plan number
001
Location
Newton, MA
Participants
597
Schedules available
Schedule H, Schedule C
Received date
not reported in the loaded dataset

Reported financial snapshot (2023)

Total assets (EOY)
$46,052,253
Total liabilities (EOY)
$0
Net assets (EOY)
$46,052,253
Employer contributions
$3,213,687
Participant contributions
$6,252,031
Total income / additions
$19,092,186
Benefits paid
$9,007,580
Administrative expenses
$50,144
Total expenses
$9,082,553
Net increase / (decrease)
$10,009,633
Schedule source
Schedule H

Reported service provider compensation (Schedule C)

Compensation reported on the 2023 filing
ProviderServiceDirect comp.Indirect comp.
Fidelity Investments InstitutionalRECORDKEEPER$50,144$0

Related Form 5500 pages